Abstract
The recognition of the gut microbial-mammalian metabolic axis and its implications in human metabolic disease opens a new window to understanding the contribution of gut microbiome to drug metabolism and drug-induced toxicity. The integrative omics approaches including pharmaco-metabonomics and metagenomics have demonstrated great promise for characterizing xenobiotic interventions that are associated with wide variation in efficacy or toxicity in humans, and predicting individual response and susceptibility to toxicity.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 9 August 2013; doi:10.1038/clpt.2013.157.
Users
Please
log in to take part in the discussion (add own reviews or comments).